Behind-The-Counter Class Requires Investment, With Payoff Unclear– GAO
This article was originally published in The Tan Sheet
A behind-the-counter drug class in the U.S. is not feasible unless the government addresses some significant logistical challenges, the Government Accountability Office says
You may also be interested in...
FDA drug center chief Janet Woodcock says behind-the-counter switches would be the most effective method to make Rx drugs available without prescriptions, particularly to help treat chronic conditions.
Boehringer Ingelheim's U.K. launch of nonprescription Flomax Relief MR for benign prostatic hyperplasia opens a new switch category abroad, but a similar Rx-to-OTC move in the U.S would be more difficult, one expert says
The court ruling overturning FDA's restricted distribution of the emergency contraceptive Plan B could have a number of implications for the biopharma industry - ranging from a near-term impact on confirmation of Obama administration nominees to a longer-term curbing of creative product risk management activities